Infections Common in IBD, Rates Vary by Treatment
Patients with inflammatory bowel disease (IBD) experienced higher rates of mild and moderate infections. Women, smokers, those with multiple comorbidities, and those with exposure to certain IBD medications showed significantly higher rates of infections.
METHODOLOGY:
Researchers conducted a prospective observational study (June 2020 to July 2021) to evaluate the incidence of and risk factors for mild, moderate, and severe infections in 629 patients (mean age, 48.3 years; 58.2% women) with IBD who used an established remote monitoring platform for IBD management.
They used the Patient-Reported Infections Questionnaire, a validated seven-item tool with a 3-month recall period, to collect data on 15 infection categories, including respiratory tract, urinary tract, and skin conditions and COVID-19.
The presence or absence of disease activity was confirmed using a combination of monitoring questionnaire scores for patient-reported disease activity and faecal calprotectin levels.
The severity of infection was categorised on the basis of the type and route of treatment as mild (self-limiting or requiring topical treatment), moderate (requiring oral treatment), or severe (requiring hospitalisation and/or intravenous treatment).
Exposure to different medications, alone or in combination, was also assessed.
TAKEAWAY:
Overall, 991 infections were reported during 573.8 person-years of follow-up, with an overall incidence rate (IR) of 172.7 per 100 person-years, predominantly comprising mild (68%; IR, 117.5 per 100 person-years) and moderate (29.5%; IR, 50.9 per 100 person-years) infections.
Women demonstrated significantly higher rates of infections than men (IR ratio [IRR], 1.70; P < .001), with increased rates of infections among current smokers vs non-smokers (IRR, 1.43; P = .004).
Patients with a Charlson Comorbidity Index score > 2 had significantly higher rates of infections than those with lower scores (IRR for all infections, 1.69; P = .031).
Glucocorticoid use more than doubled the rates of infections (IRR, 2.02; P = .033), and compared with no treatment, the use of JAK inhibitors, immunomodulator monotherapy, anti-TNF monotherapy, and combination therapy with anti-TNF and immunomodulators were associated with increased rates of infections.
IN PRACTICE:
"Clinicians should adopt a holistic approach that includes vigilant monitoring, preferably using validated tools, such as the PRIQ [Patient-Reported Infections Questionnaire], to identify patients with frequent mild or moderate infections. In addition, proactive application of preventive strategies, like vaccination, optimizing nutritional status, counselling for lifestyle modifications, and careful selection of therapies, should be used to reduce infection risk," the authors of the study wrote.
SOURCE:
This study was led by Ashkan Rezazadeh Ardabili, MD, Department of Gastroenterology and Hepatology, Maastricht University Medical Centre+, Maastricht, the Netherlands. It was published online on July 09, 2025, in the Journal of Crohn's and Colitis.
LIMITATIONS:
The study's 1‐year follow‐up coincided with COVID‐19 public health measures, likely underestimating overall rates of infections. This study was underpowered to precisely assess rare outcomes, and its real‐world design limited the control over the distribution of medication groups, especially when stratifying the analysis by IBD subtype.
DISCLOSURES:
This study was supported in part by an investigator-initiated research grant from Takeda. Some authors reported receiving grants, non-financial support, and research prizes and serving as speaker, advisor, and/or principal investigator for various institutions and pharmaceutical companies, including Takeda.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
a day ago
- Medscape
Mindfulness Therapy Aids IBD Patients With Mental Distress
TOPLINE: Mindfulness-based cognitive therapy reduced psychological distress and improved well-being of patients with inflammatory bowel disease (IBD), and it may offer benefits for sleep quality and inflammation. METHODOLOGY: Even in remission, many patients with IBD experience anxiety, depression, fatigue, and poor sleep, which can lower their quality of life, undermine self-care, and drive up healthcare use. Researchers conducted this trial in the Netherlands between July 2021 and May 2022 to strengthen the evidence for the effectiveness of mindfulness-based cognitive therapy in reducing psychological distress in patients with IBD who had been in remission for at least 3 months and experienced at least mild levels of distress. They randomly assigned 142 patients (mean age, 48.6 years; 64.1% women) to receive either mindfulness therapy plus usual treatment (n = 70; intervention group) or only usual treatment (n = 72; control group); the follow-up period lasted 12 months. The mindfulness therapy program included eight weekly group sessions of 2.5 hours, 30-45 minutes of daily home practice, and a 6-hour silent retreat day between sessions six and seven. Usual treatment included pharmacologic and surgical disease control treatments and the prevention of complications. The primary outcome was psychological distress post-intervention (3 months from baseline), measured using the Hospital Anxiety and Depression Scale (HADS) total score. Secondary outcomes included well-being, sleep, self-compassion, mindfulness skills, and disease activity. TAKEAWAY: Patients in the intervention group vs the control group showed reduced psychological distress (Cohen d [d], -0.61) and an improvement in the HADS total score (unstandardized coefficient B, -3.4; P < .001) at 3 months from baseline. The HADS total scores remained lower in the intervention group vs the control group during the entire 12-month follow-up duration. Compared with patients in the control group, those in the intervention group showed improved well-being (d, 0.41) and increases in mindfulness skills (d, 0.46) and self-compassion (d, 0.42). Patients in the intervention group vs the control group had a reduced total sleep time (d, -0.67) but an increased proportion of deep sleep (d, 0.7). No between-group difference was observed in the occurrence of disease flares, but patients in the control group showed a significant reduction in fecal calprotectin levels, an indicator of intestinal inflammation compared with patients in the control group (d, -0.49). IN PRACTICE: 'Our results demonstrate that MBCT [mindfulness-based cognitive therapy] could be a valuable addition to the currently limited number of psychological treatment options for patients with IBD with psychological distress. The group format of MBCT allows for the simultaneous treatment of more patients, potentially making it more cost-effective than individual therapy. Additionally, group therapy provides opportunities for peer support,' the authors of the study wrote. SOURCE: This study, led by Milou M. ter Avest, MD, Department of Psychiatry, Centre for Mindfulness, Radboud University Medical Centre, Nijmegen, the Netherlands, was published online in Inflammatory Bowel Diseases. LIMITATIONS: This study was limited by its unblinded design, risking expectation bias in self-reports. Mindfulness teachers had varied competence levels, which may have introduced bias. The study did not assess sleep disorders such as obstructive sleep apnea, narcolepsy, or restless legs syndrome that may have affected the sleep metrics. Additionally, electroencephalography headbands were not available for all patients, and technical and self-application issues may have led to unusable nights and data loss. DISCLOSURES: This trial was supported by ZonMw (the Netherlands Organisation for Health Research and Development) and the MindMore Foundation. Two authors reported serving on the advisory boards of various pharmaceutical companies, and one of them also reported receiving a grant from Royal DSM. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
a day ago
- Medscape
Caution Needed in Prescribing IBD Meds in CKD
TOPLINE: Most inflammatory bowel disease (IBD) therapies — particularly biologic agents — appear safe in patients with chronic kidney disease (CKD); however, caution is required with certain conventional therapies, including immunomodulators and aminosalicylates, as well as with JAK inhibitors. METHODOLOGY: From 4%-23% of patients with IBD also have renal disease, which can affect how the body processes medications; however, little data is available to guide physicians in choosing safe and effective IBD treatments for patients with advanced CKD. Researchers conducted a review of studies about IBD treatments in the setting of CKD by searching MEDLINE and EMBASE through March 31, 2025, using relevant keywords. IBD treatments evaluated were corticosteroids, aminosalicylates, immunomodulators (such as thiopurines and methotrexate), calcineurin inhibitors, biologics (such as monoclonal antibodies against tumor necrosis factors (anti-TNFs), integrin receptors, and interleukins), and small molecules (such as JAK inhibitors and sphingosine-1-phosphate [S1P] receptor modulators). TAKEAWAY: Corticosteroids in advanced kidney disease, including in patients requiring dialysis, do not require dosage adjustment. Budesonide is preferred over prednisolone, and corticosteroids are typically administered at the lowest effective dose for the shortest duration. Mesalazine, an aminosalicylate, can trigger acute interstitial nephritis; the immunomodulator methotrexate, even at 2-4 mg/wk, may cause irreversible renal decline, profound myelosuppression, and higher mortality in patients with end-stage kidney disease on hemodialysis; and calcineurin inhibitors can be nephrotoxic by reducing renal blood flow and glomerular filtration rate. Monoclonal antibodies, including anti-TNF, anti-integrin, and anti-interleukin 12/23 therapies, demonstrated safety in renal insufficiency and hemodialysis. For JAK inhibitors and thiopurines, dose adjustments were recommended in advanced renal disease, whereas S1P receptor modulators could be used in CKD without any dose adjustments. IN PRACTICE: 'Selecting appropriate therapeutics for managing IBD in patients with CKD necessitates a tailored approach, emphasizing diligent surveillance of renal function to optimize treatment efficacy and minimize renal compromise. Dose adjustments of IBD therapeutics are not required for patients with stage I or II CKD. Depending on specific drug metabolism and renal excretion, dose adjustments may be required at more advanced-stage CKD,' the authors wrote. SOURCE: The study, led by Lynna Chen, Eastern Health Clinical School, Monash University in Melbourne, Australia, was published online in Alimentary Pharmacology & Therapeutics. LIMITATIONS: This review did not discuss limitations. DISCLOSURES: The authors received no specific funding for this work. Two authors disclosed receiving advisory fees and serving as speakers for various pharmaceutical companies. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Health Line
3 days ago
- Health Line
Anxiety Diagnosis
Key takeaways Diagnosing anxiety requires a comprehensive approach, including a physical examination and a thorough review of your personal history to rule out other medical conditions that may mimic anxiety symptoms. Various self-assessment questionnaires and clinical assessments, such as the Zung Self-Rating Anxiety Scale and the Hamilton Anxiety Scale, are used to evaluate the level and severity of anxiety. Effective management of anxiety involves a combination of medication, therapy, lifestyle adjustments, and open communication with family and friends. Read on to learn more about the process of diagnosing anxiety. During the physical examination You should be completely honest with your doctor. Many things can contribute to or be affected by anxiety, including: certain illnesses medications alcohol consumption coffee consumption hormones Other medical conditions can cause symptoms that resemble anxiety. Many anxiety symptoms are physical, including: racing heart shortness of breath shaking sweating chills hot flashes chest pain twitching dry mouth nausea vomiting diarrhea frequent urination Your doctor may perform a physical exam and order a variety of tests to rule out medical conditions that mimic anxiety symptoms. Medical conditions with similar symptoms include: heart attack angina mitral valve prolapse tachycardia asthma hyperthyroidism adrenal gland tumors menopause side effects of certain drugs, such as drugs for high blood pressure, diabetes, and thyroid disorders withdrawal from certain drugs, such as those used to treat anxiety and sleep disorders substance abuse or withdrawal Diagnostic tests It's suggested that you complete a self-assessment questionnaire before other testing. This can help you decide whether you may have an anxiety disorder or if you may be reacting to a certain situation or event. If your self-assessments lead you to believe that you may have an anxiety disorder, your doctor may then ask you to take a clinical assessment or conduct a structured interview with you. Your doctor may use one or more of the following tests to assess your level of anxiety. Zung Self-Rating Anxiety Scale The Zung test is a 20-item questionnaire. It asks you to rate your anxiety from 'a little of the time' to 'most of the time' on subjects such as: nervousness anxiety shaking rapid heartbeat fainting frequent urination nightmares Once you complete this test, a trained professional assesses your responses. Hamilton Anxiety Scale (HAM-A) Developed in 1959, the Hamilton test was one of the first rating scales for anxiety. It's still widely used in clinical and research settings. It involves 14 questions that rate moods, fears, and tension, as well as physical, mental, and behavioral traits. A professional must administer the Hamilton test. Beck Anxiety Inventory (BAI) The BAI helps measure the severity of your anxiety. You can take the test by yourself. It may also be given orally by a professional or paraprofessional. There are 21 multiple-choice questions that ask you to rate your experience of symptoms during the past week. These symptoms include tingling, numbness, and fear. Answer options include 'not at all,' 'mildly,' 'moderately,' or 'severely.' Social Phobia Inventory (SPIN) This 17-question self-assessment measures your level of social phobia. You rate your anxiety in relation to various social situations on a scale from zero to four. Zero indicates no anxiety. Four indicates extreme anxiety. Penn State Worry Questionnaire This test is the most widely used measure of worry. It distinguishes between social anxiety disorder and generalized anxiety disorder. The test uses 16 questions to measure your worry's generality, excessiveness, and uncontrollability. Generalized Anxiety Disorder Scale This seven-question test is a screening tool for generalized anxiety disorder. You're asked how often in the past two weeks you've been bothered by feelings of irritability, nervousness, or fear. Options include 'not at all,' 'several days,' 'more than half the days,' or 'nearly every day.' Yale-Brown Obsessive-Compulsive Scale (YBOCS) The YBOCS is used to measure levels of OCD. It's conducted as a one-on-one interview between you and a mental health professional. You choose three items from a symptom checklist that are the most disturbing and then rate how severe they are. Then, you're asked whether you've had certain other obsessions or compulsions in the past. Based on your answers, the mental health professional grades your OCD as subclinical, mild, moderate, severe, or extreme. Mental health disorders that feature anxiety Anxiety is a symptom in several disorders. Some of these include: Disorder Symptoms Panic disorder High amounts of anxiety as well as physical stress for a short amount of time; physical stress can come in the form of dizziness, a high heart rate, sweating, numbness, and other similar symptoms Obsessive-compulsive disorder (OCD) Anxiety expressed as obsessive thoughts or as compulsive behavior that's acted upon repeatedly to relieve stress Phobias Anxiety triggered because of a specific thing or situation that isn't necessarily harmful or dangerous, including animals, heights, or riding in vehicles Social phobias Anxiety that's experienced in interpersonal situations, such as during conversations, in large social groups, or when speaking in front of a crowd The broadest anxiety disorder, generalized anxiety disorder (GAD), is different from these other disorders because it doesn't necessarily relate to a specific cause or behavior. With GAD, you may worry about many different things at once or over time, and the worries are often constant. Diagnostic criteria An anxiety diagnosis depends a lot on your description of the symptoms you're experiencing. Mental health professionals use the 'Diagnostic and Statistical Manual of Mental Disorders' (often called the DSM) to diagnose anxiety and other mental disorders based on symptoms. The criteria differ for each anxiety disorder. The DSM lists the following criteria for generalized anxiety disorder (GAD): excessive anxiety and worry most days about many things for at least six months difficulty controlling your worry appearance of three of the following six symptoms: restlessness, fatigue, irritability, muscle tension, sleep disturbance, and difficulty concentrating symptoms significantly interfering with your life symptoms not being caused by direct psychological effects of medications or medical conditions symptoms aren't due to another mental disorder (e.g. anxiety about oncoming panic attacks with panic disorder, anxiety due to a social disorder, etc.) Anxiety diagnosis in children Childhood and the teenage years are full of new, frightening experiences and events. Some children learn to confront and accept these fears. However, an anxiety disorder can make it difficult or impossible for a child to cope. The same diagnostic criteria and assessments that are used for adults apply to children, too. In the Anxiety and Related Disorders Interview Schedule for DSM-5 (ADIS-5), your doctor interviews both you and your child about their symptoms. Symptoms in children are similar to those in adults. If you notice anxiety symptoms or any anxious or worrying behaviors that last for more than two weeks, take your child to the doctor. There, they can be checked for an anxiety disorder. Some research suggests that anxiety can have a genetic component. If anyone in your family has ever been diagnosed with anxiety or a depressive disorder, get your child evaluated as soon as you notice symptoms. A proper diagnosis can lead to interventions to help them manage anxiety at a young age. What to do if you're diagnosed with anxiety Focus on managing your anxiety rather than on ending or curing it. Learning how best to control your anxiety can help you live a more fulfilled life. You can work on stopping your anxiety symptoms from getting in the way of reaching your goals or aspirations. To help manage your anxiety, you have several options. Medication If you or your child is diagnosed with anxiety, your doctor will likely refer you to a psychiatrist who can decide what anxiety medications will work best. Sticking to the recommended treatment plan is crucial for the medications to work effectively. Try not to delay your treatment. The earlier you begin, the more effective it will be. Therapy You might also consider seeing a therapist or joining a support group for people with anxiety so that you can talk openly about your anxiety. This can help you control your worries and get to the bottom of what triggers your anxiety. Lifestyle choices Find active ways to relieve your stress. This can lessen the impact that anxiety may have on you. Some things you can do include: Get regular exercise. Find hobbies that engage or occupy your mind. Participate in activities that you enjoy. Keep a daily journal of thoughts and activities. Create short-term or long-term schedules. Socialize with friends. Also, avoid alcohol, nicotine, and other similar drugs. The effects of these substances can make your anxiety worse. Communication Be open with your family and close friends about your diagnosis, if possible. It's not easy to talk about any mental disorder. However, the more the people around you understand your anxiety, the easier it becomes to communicate your thoughts and needs to them. Anxiety relief tips Stick to the treatment plan recommended by your psychiatrist. Consider seeing a therapist or joining a support group for people with anxiety. Find active ways to relieve your stress, such as getting regular exercise or keeping a daily journal. Be open with your family and close friends about your diagnosis, if possible. Avoid alcohol, nicotine, and other similar drugs. Focus on managing your anxiety rather than on ending or curing it.
